Skip to content
Original Research
J Clin Psychiatry
August 2025
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial
Full Article
Read the complete peer-reviewed article in J Clin Psychiatry.
Clinical Summary
Many adults with major depressive disorder remain symptomatic despite an adequate antidepressant trial, and augmentation options are often limited by motor, metabolic, prolactin, or weight-related adverse effects. This trial addresses a common treatment impasse: whether adjunctive lumateperone 42 mg can improve depressive symptoms in patients with inadequate antidepressant response without adding major safety burden.
FAQ
What did this trial find about lumateperone added to an antidepressant for major depressive disorder?
11 questions
Key Takeaways
Improvement emerged early: the discussion notes clinically meaningful, significant benefits by day 8 that persisted through day 43, which may matter when augmentation is being considered for symptomatic patients who cannot wait 6–12 weeks for additional benefit.
6 takeaways
Clinical Guide
How should clinicians identify appropriate adults with major depressive disorder for adjunctive lumateperone 42 mg and monitor the first 6 weeks of treatment?
9 steps
